17P Louisiana Resource Center
The Department of Health and Hospitals' Birth Outcomes Initiative and the Louisiana Hospital Association have partnered in an effort to streamline the ordering process for 17 Hydroxy-Progesterone and/or Makena. Research has shown that hormone treatment with 17 hydroxyprogesterone caproate (17P) is effective in reducing the rate of repeat preterm birth by approximately 33 percent in appropriate candidates.
Although Medicaid has been paying for the hormone for more than a year, it is clear when we review the billing data that providers are not billing appropriately and/or are vastly underutilizing the medication. A statewide survey of Obstetrical providers revealed that the primary barrier was difficulty ordering the medication. This website was created to facilitate and ease the ordering process so that every eligible woman in the state of Louisiana will get the chance to prevent another preterm birth. In addition, billing information is included so that providers can be paid for administration of this important medication.
Partners Supporting This Initiative